Results 71 to 80 of about 18,746 (183)

Family Caregiver Burden and Neuropsychiatric Symptoms in Japanese Community‐Dwelling People With Alzheimer's Disease: A Cross‐Sectional Study Using a Web‐Based Questionnaire

Psychogeriatrics, Volume 26, Issue 2, March 2026.
ABSTRACT Background Previous studies of community‐dwelling people with Alzheimer's disease (AD) have reported an association between the severe neuropsychiatric symptoms (NPS) of dementia and caregiver burden. We explored the current status of family caregiver burden, NPS of dementia, and care service usage in Japanese community‐dwelling people with AD.
Tomoyuki Nagata, Shunichiro Shinagawa, Shinichi Noto, Kentaro Yamato, Naoki Mori, Keisuke Onuki   +5 more
wiley   +1 more source

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice

Patient Preference and Adherence, 2013
Secundino López-Pousa,1 Francisco Javier Arranz21Unit for Assessment of Memory and Dementia, Institut d’Assistència Sanitària de Girona, Salt, Girona, 2CNS Area, Medical Department and Health Innovation, Esteve,
López-Pousa S, Arranz FJ
doaj  

Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis.

PLoS ONE
Background & aimsGait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait disorders, which are associated with cholinergic deficits.
Sung Ryul Shim, Jong-Yeup Kim, Kyum-Yil Kwon, Jieun Shin, Yungjin Lee, Seon-Min Lee   +5 more
doaj   +1 more source

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

Dementia and Geriatric Cognitive Disorders Extra, 2011
Background: As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer’s disease (AD) in 64 countries. Methods: This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety and ...
Yu Nakamura, Yukimichi Imai, Masahiro Shigeta, Ana Graf, Toru Shirahase, Hyosung Kim, Akifumi Fujii, Joji Mori, Akira Homma   +8 more
doaj   +1 more source

Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors. [PDF]

, 2010
Background: This study examines the joint effect on cognition of selective serotonin re-uptake inhibitors (SSRIs) and cholinesterase inhibitors (AChEIs) in depressed patients affected by Alzheimer’s disease (AD) living at home.
Bertoletti E, Conti M, Padovani A., Rozzini L., Trabucchi M, Vicini Chilovi B., Zanetti M   +6 more
core   +1 more source

Crossing the Blood–Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy

Advanced Science, Volume 13, Issue 7, 3 February 2026.
Molecularly imprinted polymeric nanocarriers (nanoMIPs) offer robust, antibody‐mimetic platforms to overcome the blood‐brain barrier. The article surveys nanoMIP design and ligand‐directed surface engineering that harness receptor‐mediated transcytosis, and highlights therapeutic and diagnostic applications in neurodegeneration, brain tumors and ...
Ranjit De, Shuliang Shi, Kyong‐Tai Kim
wiley   +1 more source

The heterogeneous treatment effects of statins on dementia: a target trial emulation with causal machine learning using integrated genetic and real‐world data

Alzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Given the complexity of dementia, the inconsistent evidence on statins and dementia highlights the need for robust methods to assess heterogeneous treatment effects (HTEs). METHODS We emulated a target trial using UK Biobank comparing statin initiators and non‐initiators aged ≥55 years.
Yongjie Lai, Qoua L Her, Yue Zhang, Hong Xu, Anna Kucharska‐Newton, Dongze Ji, Guorong Wu, Gwenn Garden, Til Stürmer, Tiansheng Wang, Yang Xu   +10 more
wiley   +1 more source

Interactions of memantine and rivastigmine with graphene oxide nanocarrier and beta-amyloid protein using molecular docking and in-silico methods

Heliyon
Alzheimer's disease is characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles. Effective therapeutic strategies involve inhibiting the formation of beta-amyloid aggregates and destabilizing existing ones.
Fateme Davoudi, Nasrin Shadjou, Mahdieh Darroudi   +2 more
doaj   +1 more source

Quality of life evidence for patients with Alzheimer’s disease: use of existing quality of life evidence from the ADENA trials to estimate the utility impact of Exelon® [PDF]

This paper utilises the Mini-Mental State Examination (MMSE) score of patients with Alzheimer’s disease to establish a relationship between disease progression and quality of life measures, and the author also compares his results to findings from the ...
Brazier, J
core   +1 more source

A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease [PDF]

, 2015
The long-term safety, tolerability, and efficacy of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer disease was evaluated in a 24-week, open-label extension to the double-blind ACTION study.
Farlow, Martin R., Grossberg, George T., Meng, Xiangyi, Sadowsky, Carl H., Velting, Drew M.   +4 more
core   +1 more source